Highbridge Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Highbridge Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-5,700	Closed	-$228K	–	1948
2017 Q3	$228K	Buy	+5,700	New	+$247K	﹤0.01%	1356
2015 Q4	–	Sell	-72,000	Closed	-$1.01M	–	1790
2015 Q3	$1.01M	Buy	+72,000	New	+$1.34M	0.02%	768
2015 Q1	–	Sell	-17,400	Closed	-$144K	–	1573
2014 Q4	$144K	Buy	+17,400	New	+$146K	﹤0.01%	1088

Other funds holding SUPN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Highbridge Capital Management's SUPN Position: Q2 2018 in Review

Highbridge Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q2 2018, closing a stake of 164,500 shares — an estimated $7.54M sold.

Highbridge Capital Management first reported a position in SUPN in Q4 2014 and held it in 6 quarters. The position peaked at $7.54M in Q1 2018. 320 funds tracked by Wall St. Rank hold SUPN as of Q2 2018.

Highbridge Capital Management reported no remaining Supernus Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 164,500 Supernus Pharmaceuticals shares in Q2 2018, an estimated $7.54M.
Highbridge Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2014 and held it in 6 quarters.
Highbridge Capital Management's Supernus Pharmaceuticals position peaked at $7.54M in Q1 2018.
320 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.